Yuasa Yasuhiro, Okitsu Hiroshi, Goto Masakazu, Edagawa Hiroshi, Mori Osamu, Tani Ryotaro, Masuda Yuri, Kuramoto Shunsuke, Matsumoto Daisuke, Tomibayashi Atsushi, Hamada Yoko, Yamashita Michiko, Fujii Yoshiyuki, Itoh Koji
Dept. of Digestive Surgery, Tokushima Red Cross Hospital.
Gan To Kagaku Ryoho. 2015 May;42(5):637-40.
In our hospital, a clinical trial on the effects of preoperative 2-week S-1 administration for advanced gastric cancer is being conducted. A7 5-year-old man presented to our hospital with a type 2 tumor(poorly differentiated adenocarcinoma)in the pyloric antrum. Subpyloric lymph node enlargement and a c-T2(MP), N1, M0, Stage II A tumor (according to the gastric cancer handling agreement, 14th edition)were diagnosed, and S-1(100mg/day)was subsequently administered for 14 days. On day 15, we performed laparoscopy-assisted distal gastrectomy, with D2 dissection. Analysis of the resected specimen, ie the primary tumor and metastatic lymph nodes, confirmed the effect of the treatment as Grade 2, and revealed a type 2 gastric cancer of 30×20mm in size; this tumor was downstaged to yp-T1b(SM), N1, Stage I B. No adverse events associated with perioperative S-1 were observed, and the postoperative course was good. At the latest follow-up(6 years after treatment), no recurrence was observed.
在我院，一项关于术前2周给予S-1对进展期胃癌疗效的临床试验正在进行。一名75岁男性因胃窦部2型肿瘤（低分化腺癌）前来我院就诊。诊断为幽门下淋巴结肿大，c-T2（肌层浸润）、N1、M0、II A期肿瘤（根据第14版胃癌处理规约），随后给予S-1（100mg/天），持续14天。第15天，我们进行了腹腔镜辅助远端胃切除术及D2淋巴结清扫。对切除标本（即原发性肿瘤和转移性淋巴结）的分析证实治疗效果为2级，并发现一个大小为30×20mm的2型胃癌；该肿瘤降期为yp-T1b（黏膜下层浸润）、N1、I B期。未观察到与围手术期S-1相关的不良事件，术后病程良好。在最近一次随访（治疗后6年）时，未观察到复发。
